Pear Therapeutics
closed- hard tech
- biotechnology
- core ai
- testing
- entertainment
- ai applications
- oncology
- open source
- aviation & aerospace
- predictive analytics
- verified unicorns and $1b exits
- genetics
- dna
- intellectual property
- neurology
- user behavior
- surgery
- cardiology
- genome engineering
- patient care
- tech for patients
- children
- tech for biotech & pharma
- spac ipo announced
- digital therapeutics
- icarus: from unicorn to failure
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 33.0m | 9.0m | 4.0m | 13.0m |
| % growth | - | (73 %) | (56 %) | 225 % |
| EBITDA | (31.0m) | (76.0m) | (103m) | (115m) |
| % EBITDA margin | (94 %) | (844 %) | (2575 %) | (885 %) |
| Profit | (9.0m) | (97.0m) | (65.0m) | (75.0m) |
| % profit margin | (27 %) | (1078 %) | (1625 %) | (577 %) |
| EV / revenue | - | - | 176.7x | 11.0x |
| EV / EBITDA | - | - | -6.9x | -1.2x |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Early VC | ||
$20.0m | Series A | ||
$50.0m | Series B | ||
$64.0m | Series C | ||
| N/A | $50.0m | Debt | |
$80.0m | Series D | ||
$20.0m Valuation: $400m 44.4x EV/LTM Revenues -5.3x EV/LTM EBITDA | Series D | ||
$276m Valuation: $1.6b 177.8x EV/LTM Revenues -21.1x EV/LTM EBITDA | SPAC IPO | ||
$125m Valuation: $1.6b 177.8x EV/LTM Revenues -21.1x EV/LTM EBITDA | SPAC Private Placement | ||
* | $50.0m Valuation: $1.6b 177.8x EV/LTM Revenues -21.1x EV/LTM EBITDA | SPAC Private Placement | |
* | N/A | N/A | Bankruptcy |
| Total Funding | €372m | ||
Recent News about Pear Therapeutics
EditPear Therapeutics is a leader in the emerging field of Prescription Digital Therapeutics (PDTs), which are software-based treatments for serious diseases. These therapeutics are designed, tested, and prescribed in a manner similar to traditional drugs but utilize software instead of pills or injections. Pear Therapeutics operates in the healthcare and technology markets, serving patients, healthcare providers, and payers. The company's business model involves developing and delivering clinically validated software that improves patient outcomes, enhances clinician engagement, and offers cost-effective solutions for payers. Revenue is generated through the prescription and use of their digital therapeutics, which are evaluated by the FDA and prescribed by healthcare providers. Pear Therapeutics focuses on integrating biology and software technology to create innovative treatments that are both safe and effective.
Keywords: Prescription Digital Therapeutics, software-based treatments, serious diseases, FDA-evaluated, patient outcomes, clinician engagement, cost-effective, healthcare technology, innovative treatments, clinically validated.